Literature DB >> 7902850

Coexpression of intercellular adhesion molecule-1 and class I major histocompatibility complex antigens on hepatocyte membrane in chronic viral hepatitis.

C M Chu1, Y F Liaw.   

Abstract

AIMS: To evaluate the role of hepatocyte expression of leucocyte adhesion molecules and major histocompatibility complex (MHC) antigens in the pathogenesis of chronic viral hepatitis.
METHODS: The expression of intercellular adhesion molecule 1 (ICAM-1), lymphocyte function associated antigen 3 (LFA-3), and MHC class I and II antigens on hepatocyte membrane in relation to the histological and biochemical activities was studied in patients with chronic B hepatitis, chronic persistent hepatitis (CPH) n = 23; chronic active hepatitis (CAH) n = 20; chronic D hepatitis (CAH) n = 6; and chronic non-A, non-B hepatitis (CPH n = 4, CAM n = 6). Six of the latter were hepatitis C virus antibody positive.
RESULTS: In chronic B hepatitis ICAM-1 and MHC-I were expressed significantly more in patients with CAH than in those with CPH (p < 0.001), while the expression of LFA-3 and MHC-II showed no significant difference, irrespective of serum HBeAg or hepatitis B virus DNA. Similar findings were noted in non-A, non-B hepatitis. Regardless of the viral aetiology, patients with CAH had a significantly higher degree of ICAM-1 and MHC-I expression than LFA-3 (p < 0.001 v ICAM-1 and MHC-I, respectively) and MHC-II (p < 0.001 v ICAM-1 and MHC-I, respectively) expression. Those with CPH showed little or no difference in the expression of these four molecules. Furthermore, serum ALT values positively correlated with the hepatocyte expression of ICAM-1 (p < 0.001) and MHC-I (p < 0.001), but not LFA-3 (p > 0.05) and MHC-II (p > 0.05).
CONCLUSIONS: In chronic viral hepatitis hepatocyte expression of ICAM-1 and MHC-I might be important for immunosurveillance against virally infected hepatocytes, while the expression of LFA-3 and MHC-II does not seem to have a role in the pathogenesis of chronic viral hepatitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902850      PMCID: PMC501682          DOI: 10.1136/jcp.46.11.1004

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  35 in total

1.  Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines.

Authors:  T Y Basham; M F Bourgeade; A A Creasey; T C Merigan
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

2.  The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions.

Authors:  A M Krensky; F Sanchez-Madrid; E Robbins; J A Nagy; T A Springer; S J Burakoff
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

3.  Involvement of the cytotoxic/suppressor T-cell subset in liver tissue injury of patients with acute and chronic liver diseases.

Authors:  G R Pape; E P Rieber; J Eisenburg; R Hoffmann; C M Balch; G Paumgartner; G Riethmüller
Journal:  Gastroenterology       Date:  1983-09       Impact factor: 22.682

4.  A novel lymphocyte function-associated antigen (LFA-1): cellular distribution, quantitative expression, and structure.

Authors:  K Kürzinger; T Reynolds; R N Germain; D Davignon; E Martz; T A Springer
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

Review 5.  The human T-cell receptor.

Authors:  S C Meuer; O Acuto; T Hercend; S F Schlossman; E L Reinherz
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

6.  Cellular and humoral immune reactions in chronic active liver disease. I. Lymphocyte subsets in liver biopsies of patients with untreated idiopathic autoimmune hepatitis, chronic active hepatitis B and primary biliary cirrhosis.

Authors:  H F Eggink; H J Houthoff; S Huitema; C H Gips; S Poppema
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

7.  Intrahepatic expression of pre-S1 and pre-S2 antigens in chronic hepatitis B virus infection in relation to hepatitis B virus replication and hepatitis delta virus superinfection.

Authors:  C M Chu; Y F Liaw
Journal:  Gut       Date:  1992-11       Impact factor: 23.059

8.  Enhancement by interferon of membrane HLA antigens in patients with combined immunodeficiency with defective HLA expression.

Authors:  A Durandy; J L Virelizier; C Griscelli
Journal:  Clin Exp Immunol       Date:  1983-04       Impact factor: 4.330

9.  Expression of beta-2-microglobulin on hepatocytes after liver transplantation.

Authors:  Y Nagafuchi; K E Hobbs; H C Thomas; P J Scheuer
Journal:  Lancet       Date:  1985-03-09       Impact factor: 79.321

10.  Immunohistochemical analysis of HLA (A, B, C) antigens in liver disease using a monoclonal antibody.

Authors:  C Barbatis; J Woods; J A Morton; K A Fleming; A McMichael; J O McGee
Journal:  Gut       Date:  1981-12       Impact factor: 23.059

View more
  4 in total

Review 1.  Intercellular adhesion molecule-1.

Authors:  A van de Stolpe; P T van der Saag
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

2.  S fimbriae of uropathogenic Escherichia coli bind to primary human renal proximal tubular epithelial cells but do not induce expression of intercellular adhesion molecule 1.

Authors:  B Kreft; M Placzek; C Doehn; J Hacker; G Schmidt; G Wasenauer; M R Daha; F J van der Woude; K Sack
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

3.  The level of viral antigen presented by hepatocytes influences CD8 T-cell function.

Authors:  Adam J Gehring; Dianxing Sun; Patrick T F Kennedy; Esther Nolte-'t Hoen; Seng Gee Lim; Shanthi Wasser; Clare Selden; Mala K Maini; Dan M Davis; Michael Nassal; Antonio Bertoletti
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

Review 4.  Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses.

Authors:  Ming-Ling Chang; Yun-Fan Liaw
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.